FOXM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, our group has demonstrated that niclosamide can eradicate leukemia stem cells (LSCs) in CML through disrupting interaction between p65 and FOXM1/β-catenin18, suggesting its activity against imatinib-resistance caused by LSCs.